| 19.83 -0.86 (-4.16%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.57 | 1-year : | 29.08 |
| Resists | First : | 22.74 | Second : | 24.89 |
| Pivot price | 21.34 |
|||
| Supports | First : | 19.27 | Second : | 16.03 |
| MAs | MA(5) : | 20.33 |
MA(20) : | 21.59 |
| MA(100) : | 23.67  |
MA(250) : | 0 | |
| MACD | MACD : | -1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 21.8 |
D(3) : | 23.6 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 33.2 | Low : | 13.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVMN ] has closed above bottom band by 23.9%. Bollinger Bands are 23.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.64 - 21.75 | 21.75 - 21.84 |
| Low: | 19.53 - 19.64 | 19.64 - 19.73 |
| Close: | 19.67 - 19.84 | 19.84 - 19.98 |
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Thu, 11 Jun 2026
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Thu, 07 May 2026
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
Thu, 12 Feb 2026
Evommune Announces $125 Million Private Placement - Business Wire
Wed, 11 Feb 2026
Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge (NYSE:EVMN) - Seeking Alpha
Tue, 10 Feb 2026
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld News
Tue, 10 Feb 2026
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 7.9 (%) |
| Held by Institutions | 110.7 (%) |
| Shares Short | 3,100 (K) |
| Shares Short P.Month | 3,460 (K) |
| EPS | -2.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.46 |
| Profit Margin | 0 % |
| Operating Margin | -900 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -45 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -2.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -80 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -9.4 |
| PEG Ratio | 0 |
| Price to Book value | 2.34 |
| Price to Sales | 71.42 |
| Price to Cash Flow | -8.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|